Abstract:Purpose: Our previous study demonstrated the benefit of cumulative dose of cisplatin during the whole treatment on locally advanced nasopharyngeal carcinoma (NPC) treated with various chemotherapy strategies. The purpose of this study is to identify the subgroup of locally advanced NPC who benefits from higher dose of cisplatin, and to clarify whether cumulative dose of cisplatin during the whole treatment brings survival benefit to those treated with concurrent chemoradiotherapy (CCRT).Materials and methods: This retrospective study enrolled 527 patients with locally advanced NPC treated with intensity-modulated radiation therapy (IMRT) and chemotherapy in our institution from 2009 to 2010. The median cumulative dose of cisplatin of 300mg/ m2 was chose to be the cutoff value of low and high dose subgroups. Survival curves were estimated using the Kaplan-Meier method. Univariate analysis was conducted using the log-rank test. Multivariate analyses (MVA) were performed using Cox proportional hazards regression model.Results: With a median follow-up of 54.5 (1-76.7) months, high-dose subgroup had a significant higher distant metastasis-free survival (DMFS) (82.0% vs. 76.5%, p= 0.029) and overall survival (OS) (84.1% vs. 74.0%, p= 0.028). Cumulative dose of cisplatin were demonstrated an independent prognostic factors for DMFS (HR= 0.524, 95% CI 0.340-0.806) and OS (HR= 0.577, 95% CI 0.373-0.893) for the entire cohort upon MVA. As for T1-2N2-3, high-dose subgroup had a trend of better DMFS (85.7% vs. 76.3%, p= 0.069) and a significant improvement in OS (87.8% vs. 76.3%, p= 0.041). Similarly, in the subgroup of T3-4N2-3, higher dose of cisplatin was associated with higher OS (80.3% vs. 52.3%, p= 0.032). Cumulative dose of cisplatin was an independent prognostic factor for DMFS (HR= 0.483, 95% CI 0.292-0.798) and OS (HR= 0.429, 95% CI 0.258-0.715) for patients with T1-4N2-3 disease upon MVA. However, the benefit of higher dose of cisplatin was not observed in the subgroup of T3-4N0-1. For patients receiving CCRT (n= 278), those treated with higher dose of cisplatin had a significantly higher DMFS (87.7% vs. 75.4%, p= 0.004). The benefit mainly derived from T3-4N2-3 patients treated with CCRT (5y DMFS: 87.9% vs. 58.2%, p= 0.034). Cumulative dose of cisplatin was associated with a lower risk of distant metastasis (HR= 0.427, 95% CI 0.228-0.801) for patients treated with CCRT upon MVA.Conclusions: Our study identified that patients with N2-3 disease were those benefited from higher cumulative dose. The benefit of higher cumulative dose maintained in those treated with CCRT. The intensity of chemotherapy may be tailored based on various stage subgroups in locally advanced NPC.

Treatment Effects of Cumulative Cisplatin Dose During Radiotherapy Following Induction Chemotherapy in Nasopharyngeal Carcinoma: Propensity Score Analyses

Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort.

Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial.

Individualised Cumulative Cisplatin Dose for Locoregionally Advanced Nasopharyngeal Carcinoma Patients Based on Induction Chemotherapy Response and Tumour Volume

The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy

Efficiency of high cumulative cisplatin dose in high‐ and low‐risk patients with locoregionally advanced nasopharyngeal carcinoma

Who Benefited Most from Higher Cumulative Dose of Cisplatin among Patients with Locally Advanced Nasopharyngeal Carcinoma Treated by Intensity-Modulated Radiation Therapy? A Retrospective Study of 527 Cases

Optimal Cumulative Cisplatin Dose in Nasopharyngeal Carcinoma Patients Based on Induction Chemotherapy Response.

Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein-Barr virus DNA level after induction chemotherapy

Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area

WITHDRAWN: Interim Analysis of a Prospective Randomized Non-Inferiority Trial of Cisplatin and Fluorouracil Induction Chemotherapy with or Without Docetaxel in Nasopharyngeal Carcinoma

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.

Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study

Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

[Concurrent Chemotherapy with Different Dose Regimens of Cisplatin for Nasopharyngeal Carcinoma Using Intensity-Modulated Radiation Therapy: a Phase II Prospective Randomized Controlled Trial].

Combined pre-treatment and middle-treatment Epstein–Barr virus DNA load contributes to prognostication and treatment modification in nasopharyngeal carcinoma patients

Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy

Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial

Propensity Score Matching Analysis of Cisplatin-Based Concurrent Chemotherapy in Low Risk Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era